Ameritas Investment Partners Inc. Has $590,000 Holdings in Glaukos Corporation $GKOS

Glaukos reported quarterly results (released Oct. 29) with an EPS loss of ($0.16) that beat consensus by $0.11 and revenue of $133.54 million, up 38.1% year‑over‑year and above estimates; the company posted negative net margin (‑18.65%) and ROE (‑7.53%) and carries a negative P/E. Institutional investors have increased stakes (e.g., Wellington 2.29M shares, Primecap 1.83M shares), several brokers upped price targets (JPMorgan to $120, Citi to $113, BTIG to $116) producing a MarketBeat consensus target of $119.08, while insiders (CFO and COO) conducted modest stock sales, and analysts project roughly -1.08 EPS for the fiscal year.

Analysis

Market structure: Institutional buying (Wellington, Primecap, AB) plus recent analyst upgrades signal growing conviction in GKOS’s MIGS (iStent) adoption; beneficiaries include Glaukos and surgical-capex suppliers, while legacy pharmaceutical-only glaucoma players lose share in mild-to-moderate OAG segments. High institutional ownership (~99%) and a relatively tight float will amplify directional moves — positive flow can compress supply and lift implied volatility; cross-asset effects are muted but expect option skew to stay elevated and small impact on credit markets given low leverage (D/E 0.09).

Risk assessment: Key tail risks are adverse CMS/reimbursement decisions, an FDA setback on pipeline products, or a sharp elective-surgery slowdown (a 10-20% drop in cataract volumes would meaningfully depress revenue). Timeframes: immediate (days) = reaction to analyst chatter and insider sales volatility; short-term (weeks–months) = execution vs FY25 EPS guidance (consensus -1.08) and volume trends; long-term (quarters) = adoption curve and margin expansion. Hidden dependencies include reliance on cataract surgery volumes and hospital procurement cycles; catalysts include Medicare coding updates, next quarterly print, and peer-reviewed outcomes data.

Trade implications: Set-up favors idiosyncratic long exposure with hedges — directional trade if you believe adoption accelerates to justify consensus PT ~$119 (up ~12% from $106), otherwise hedge beta. Options: use defined-risk debit spreads to capture 3–12 month adoption upside while limiting premium loss. Sector: overweight specialty medtech/ophthalmology vs broad pharma where pricing power is weaker.

Contrarian angles: Consensus (Moderate Buy, PT ~$119) underestimates operational leverage if revenue growth sustains >30% y/y and margins improve; it also overlooks downside from reimbursement squeeze. Insider selling (COO large sale) is a warning flag — could be tax/diversification but increases tail risk. Historical parallels: prior device adoption cycles show nonlinear takeoff after reimbursement clarity; liquidity constraints from concentrated ownership can exacerbate both rallies and drawdowns.

Key Decisions for Investors

• Establish a 2–3% long position in GKOS at market or on pullbacks to $86–$95 (50-day to 200-day MA zone). Target take-profit at $140 within 6–12 months (≈+32% from $106) and set a tactical stop-loss at $80 (≈-25%).
• Buy a 6–9 month GKOS call spread (long 100C / short 130C) sized to ~1–1.5% notional to capture upside to $120–$130 while capping premium; roll or unwind on close above $130 or if implied vol rises >40%.
• Execute a relative-value hedge: long GKOS 2% vs short IHI (iShares U.S. Medical Devices ETF) 1.5% to neutralize broader device beta and isolate GKOS-specific adoption risk for 3–6 months.
• Sell cash-secured puts at $95 with 30–60 day expiries (collect premium) to acquire GKOS at an effective net basis ≲$90 if assigned; if already long, sell covered calls at $120 for 2–3 months to monetize upside toward consensus PT.